Johnson & Johnson (JNJ)
Develops prescription medicines and cardiovascular, surgical, orthopaedic and vision technologies.
$269.61
After hours+0.32 (+0.12%)
At close$269.29(−0.07%)
Something off on this page? Send us feedback.
Next report
Oct 13, 26
in 21 days
EPS estimate
$2.85
Revenue estimate
$25.35B
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Jan '25Apr '25Jul '25Oct '25Jan '26Apr '26Jul '26Oct '26
Reported$2.04$2.77$2.77$2.80$2.46$2.70$2.90Pending
Estimate$1.99$2.58$2.68$2.76$2.46$2.68$2.84$2.85
Surprise+2.5%+7.4%+3.4%+1.4%0.0%+0.7%+2.1%—
RevenueReportedEstimate
Jan '25Apr '25Jul '25Oct '25Jan '26Apr '26Jul '26Oct '26
Reported$22.52B$21.89B$23.74B$23.99B$24.56B$24.06B$25.31BPending
Estimate$22.43B$21.56B$22.85B$23.76B$24.15B$23.61B$25.06B$25.35B
Surprise+0.4%+1.6%+3.9%+1.0%+1.7%+1.9%+1.0%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2028 | $3.51 | — | — |
| Sep 2028 | $3.59 | — | — |
| Jun 2028 | $3.40 | — | — |
| Mar 2028 | $3.09 | — | — |
| Dec 2027 | $3.32 | — | — |
| Sep 2027 | $3.29 | — | — |
| Jun 2027 | $3.14 | — | — |
| Mar 2027 | $2.92 | — | — |
| Dec 2026 | $3.00 | — | — |
| Oct 2026 | $2.85 | — | — |
| Jul 2026 | $2.84 | $2.90 | +2.1% |
| Apr 2026 | $2.68 | $2.70 | +0.7% |
| Jan 2026 | $2.46 | $2.46 | 0.0% |
| Oct 2025 | $2.76 | $2.80 | +1.4% |
| Jul 2025 | |||
| Apr 2025 | |||
| Jan 2025 | |||
| Oct 2024 | |||
| Jul 2024 | |||
| Apr 2024 | |||
| Jan 2024 | |||
| Oct 2023 | |||
| Jul 2023 | |||
| Apr 2023 | |||
| Jan 2023 | |||
| Oct 2022 | |||
| Jul 2022 | |||
| Apr 2022 | |||
| Jan 2022 | |||
| Oct 2021 | |||
| Jul 2021 | |||
| Apr 2021 | |||
| Jan 2021 | |||
| Oct 2020 | |||
| Jul 2020 | |||
| Apr 2020 | |||
| Jan 2020 | |||
| Oct 2019 | |||
| Jul 2019 | |||
| Apr 2019 | |||
| Jan 2019 | |||
| Oct 2018 | |||
| Jul 2018 | |||
| Apr 2018 | |||
| Jan 2018 | |||
| Oct 2017 | |||
| Jul 2017 | |||
| Apr 2017 | |||
| Jan 2017 | |||
| Oct 2016 | |||
| Jul 2016 | |||
| Apr 2016 | |||
| Jan 2016 | |||
| Oct 2015 | |||
| Jul 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2028 | $3.51 | — | — | $30.45B | — | — | — |
| Sep 2028 | $3.59 | — | — | $28.80B | — | — | — |
| Jun 2028 | $3.40 | — | — | $28.27B | — | — | — |
| Mar 2028 | $3.09 | — | — | $26.53B | — | — | — |
| Dec 2027 | $3.32 | — | — | $28.14B | — | — | — |
| Sep 2027 | $3.29 | — | — | $27.03B | — | — | — |
| Jun 2027 | $3.14 | — | — | $26.92B | — | — | — |
| Mar 2027 | $2.92 | — | — | $25.49B | — | — | — |
| Dec 2026 | $3.00 | — | — | $26.45B | — | — | — |
| Oct 13, 2026 | $2.85 | — | — | $25.35B | — | — | — |
| Jul 15, 2026 | $2.84 | $2.90 | +2.1% | $25.06B | $25.31B | +1.0% | −2.7% |
| Apr 14, 2026 | $2.68 | $2.70 | +0.7% | $23.61B | $24.06B | +1.9% | +0.9% |
| Jan 21, 2026 | $2.46 | $2.46 | 0.0% | $24.15B | $24.56B | +1.7% | −0.1% |
| Oct 14, 2025 | $2.76 | $2.80 | +1.4% | $23.76B | $23.99B | +1.0% | −0.0% |
| Jul 16, 2025 | |||||||
| Apr 15, 2025 | |||||||
| Jan 22, 2025 | |||||||
| Oct 15, 2024 | |||||||
| Jul 17, 2024 | |||||||
| Apr 16, 2024 | |||||||
| Jan 23, 2024 | |||||||
| Oct 17, 2023 | |||||||
| Jul 20, 2023 | |||||||
| Apr 18, 2023 | |||||||
| Jan 24, 2023 | |||||||
| Oct 18, 2022 | |||||||
| Jul 19, 2022 | |||||||
| Apr 19, 2022 | |||||||
| Jan 25, 2022 | |||||||
| Oct 19, 2021 | |||||||
| Jul 21, 2021 | |||||||
| Apr 20, 2021 | |||||||
| Jan 26, 2021 | |||||||
| Oct 13, 2020 | |||||||
| Jul 16, 2020 | |||||||
| Apr 14, 2020 | |||||||
| Jan 22, 2020 | |||||||
| Oct 15, 2019 | |||||||
| Jul 16, 2019 | |||||||
| Apr 16, 2019 | |||||||
| Jan 22, 2019 | |||||||
| Oct 16, 2018 | |||||||
| Jul 17, 2018 | |||||||
| Apr 17, 2018 | |||||||
| Jan 23, 2018 | |||||||
| Oct 17, 2017 | |||||||
| Jul 18, 2017 | |||||||
| Apr 18, 2017 | |||||||
| Jan 24, 2017 | |||||||
| Oct 18, 2016 | |||||||
| Jul 19, 2016 | |||||||
| Apr 19, 2016 | |||||||
| Jan 26, 2016 | |||||||
| Oct 13, 2015 | |||||||
| Jul 14, 2015 |